Colony-Stimulating Factors in the Therapeutic Approach to Sepsis

Area of Science:

• Critical Care Medicine
• Hematology
• Infectious Diseases

Background:

• Sepsis remains a primary cause of mortality in the US, despite advanced antimicrobial therapies.
• Neutropenia, a common complication, increases susceptibility to severe infections and mortality.
• Colony-stimulating factors (CSFs) are known to modulate leukocyte production.

Purpose of the Study:

• To review current data on the efficacy and safety of CSFs in managing sepsis.
• To evaluate the impact of CSFs on leukocyte counts and neutropenic duration in septic patients.
• To determine the clinical benefit of CSFs in improving outcomes for neutropenic sepsis.

Main Methods:

• Comprehensive review of in vitro, ex vivo, animal, and human studies.
• Analysis of data on leukocyte count changes and duration of neutropenia.
• Evaluation of clinical outcomes in septic patients receiving CSFs.

Main Results:

• CSFs (granulocyte CSFs and granulocyte-macrophage CSFs) effectively increase leukocyte counts.
• CSFs shorten the duration of neutropenic days in treated patients.
• Some studies indicate improved outcomes in neutropenic sepsis, particularly with early CSF administration; however, other studies show no significant benefit.

Conclusions:

• CSFs are generally safe for use in septic patients.
• Their use should be considered for neutropenic septic patients with anticipated prolonged neutropenia or severe illness.
• Further research may clarify the specific subgroups of septic patients who benefit most from CSF therapy.